🎉 M&A multiples are live!
Check it out!

BridgeBio Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for BridgeBio Pharma and similar public comparables like Pharming, Benevolent AI, and Vivoryon Therapeutics.

BridgeBio Pharma Overview

About BridgeBio Pharma

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.


Founded

2019

HQ

United States of America
Employees

730

Website

bridgebio.com

Financials

LTM Revenue $226M

LTM EBITDA -$581M

EV

$7.7B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

BridgeBio Pharma Financials

BridgeBio Pharma has a last 12-month revenue of $226M and a last 12-month EBITDA of -$581M.

In the most recent fiscal year, BridgeBio Pharma achieved revenue of $222M and an EBITDA of -$437M.

BridgeBio Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See BridgeBio Pharma valuation multiples based on analyst estimates

BridgeBio Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $9.3M $222M XXX XXX XXX
Gross Profit $74.2M $6.9M XXX XXX XXX
Gross Margin 798% 3% XXX XXX XXX
EBITDA -$565M -$437M XXX XXX XXX
EBITDA Margin -6078% -197% XXX XXX XXX
Net Profit -$481M -$643M XXX XXX XXX
Net Margin -5172% -290% XXX XXX XXX
Net Debt $1.3B $1.4B XXX XXX XXX

Financial data powered by Morningstar, Inc.

BridgeBio Pharma Stock Performance

As of April 15, 2025, BridgeBio Pharma's stock price is $35.

BridgeBio Pharma has current market cap of $6.6B, and EV of $7.7B.

See BridgeBio Pharma trading valuation data

BridgeBio Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$7.7B $6.6B XXX XXX XXX XXX $-3.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

BridgeBio Pharma Valuation Multiples

As of April 15, 2025, BridgeBio Pharma has market cap of $6.6B and EV of $7.7B.

BridgeBio Pharma's trades at 33.9x LTM EV/Revenue multiple, and -13.2x LTM EBITDA.

Analysts estimate BridgeBio Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for BridgeBio Pharma and 10K+ public comps

BridgeBio Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $7.7B XXX XXX XXX
EV/Revenue 34.6x XXX XXX XXX
EV/EBITDA -17.6x XXX XXX XXX
P/E -12.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -14.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BridgeBio Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

BridgeBio Pharma Valuation Multiples

BridgeBio Pharma's NTM/LTM revenue growth is 43%

BridgeBio Pharma's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.1M for the same period.

Over next 12 months, BridgeBio Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate BridgeBio Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for BridgeBio Pharma and other 10K+ public comps

BridgeBio Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 2285% XXX XXX XXX XXX
EBITDA Margin -197% XXX XXX XXX XXX
EBITDA Growth -23% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -154% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 228% XXX XXX XXX XXX
Opex to Revenue 358% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

BridgeBio Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

BridgeBio Pharma M&A and Investment Activity

BridgeBio Pharma acquired  XXX companies to date.

Last acquisition by BridgeBio Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . BridgeBio Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by BridgeBio Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About BridgeBio Pharma

When was BridgeBio Pharma founded? BridgeBio Pharma was founded in 2019.
Where is BridgeBio Pharma headquartered? BridgeBio Pharma is headquartered in United States of America.
How many employees does BridgeBio Pharma have? As of today, BridgeBio Pharma has 730 employees.
Who is the CEO of BridgeBio Pharma? BridgeBio Pharma's CEO is Dr. Neil Kumar, PhD.
Is BridgeBio Pharma publicy listed? Yes, BridgeBio Pharma is a public company listed on NAS.
What is the stock symbol of BridgeBio Pharma? BridgeBio Pharma trades under BBIO ticker.
When did BridgeBio Pharma go public? BridgeBio Pharma went public in 2019.
Who are competitors of BridgeBio Pharma? Similar companies to BridgeBio Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of BridgeBio Pharma? BridgeBio Pharma's current market cap is $6.6B
What is the current revenue of BridgeBio Pharma? BridgeBio Pharma's last 12-month revenue is $226M.
What is the current EBITDA of BridgeBio Pharma? BridgeBio Pharma's last 12-month EBITDA is -$581M.
What is the current EV/Revenue multiple of BridgeBio Pharma? Current revenue multiple of BridgeBio Pharma is 33.9x.
What is the current EV/EBITDA multiple of BridgeBio Pharma? Current EBITDA multiple of BridgeBio Pharma is -13.2x.
What is the current revenue growth of BridgeBio Pharma? BridgeBio Pharma revenue growth between 2023 and 2024 was 2285%.
Is BridgeBio Pharma profitable? Yes, BridgeBio Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.